Clinical characteristics and overall survival of patients with myeloproliferative neoplasms in blast phase according to different treatment approaches
Latest Information Update: 31 Jan 2022
At a glance
- Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Cytarabine/daunorubicin (Primary) ; Daunorubicin (Primary) ; Idarubicin (Primary) ; Mitoxantrone (Primary) ; Venetoclax (Primary) ; DNA methylation inhibitors
- Indications Myeloproliferative disorders; Tumours
- Focus Therapeutic Use
- 31 Jan 2022 New trial record
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition